Skip to main content
Premium Trial:

Request an Annual Quote

Bruker Posts 16 Percent Q4 Revenue Growth, Surpasses Preliminary Results

By a GenomeWeb staff reporter

NEW YORK (GenomeWeb News) – Bruker today reported fourth-quarter 2009 revenue growth of 16 percent, or 6 percent excluding the effects of foreign currency translation. The firm's Q4 results beat preliminary expectations announced by the firm just three weeks ago.

Bruker generated total revenues of $366.4 million for the three-month period ended Dec. 31, 2009, compared to $315.2 million for Q4 2008. Its revenues surpassed preliminary expectations of $340 million announced in January and $355 million announced earlier this month. In addition, it easily beat analysts' consensus estimate of $334.9 million.

The firm's Scientific Instruments segment had revenue growth of 13 percent year over year to 4346.2 million from $306.8 million, while its Energy & Supercon Technologies segment had 116 percent revenue growth.

Bruker's profit for the quarter was $43.6 million, or $.26 per share, up from $26.2 million, or $.16 per share, for the fourth quarter of 2008. The Q4 2008 profit was negatively affected by a $2.3 restructuring charge. The firm beat analysts' estimates of $.21 per share in Q4 2009.

The firm's R&D spending increased 5 percent to $34.6 million from $33 million, while its SG&A spending jumped 12 percent to $73.9 million from $66.1 million.

For full-year 2009, Bruker's revenues increased 1 percent to $1.114 billion from $1.107 billion. Excluding currency effects, its revenue growth was 2 percent year over year.

The firm's Scientific Instruments segment had a year over year revenue decline of 1 percent to $1.06 billion from $1.07 billion. Its Energy & Supercon Technologies segment had revenue growth of 37 percent to $59.8 million from $43.5 million.

Bruker's net income for full-year 2009 was $81 million, or $.49 per share, compared to $65.2 million, or $.39 per share for FY 2008.

The firm's R&D spending for the year declined 6 percent to $126.4 million from $133.8 million, while its SG&A spending was nearly flat at $255.3 million versus $254.5 million.

Bruker finished the year with $209.1 million in cash, cash equivalents, and restricted cash.

The firm said in a statement that its financial goals for 2010 include currency-adjusted revenue growth of greater than 5 percent.

The Scan

Genetic Risk Factors for Hypertension Can Help Identify Those at Risk for Cardiovascular Disease

Genetically predicted high blood pressure risk is also associated with increased cardiovascular disease risk, a new JAMA Cardiology study says.

Circulating Tumor DNA Linked to Post-Treatment Relapse in Breast Cancer

Post-treatment detection of circulating tumor DNA may identify breast cancer patients who are more likely to relapse, a new JCO Precision Oncology study finds.

Genetics Influence Level of Depression Tied to Trauma Exposure, Study Finds

Researchers examine the interplay of trauma, genetics, and major depressive disorder in JAMA Psychiatry.

UCLA Team Reports Cost-Effective Liquid Biopsy Approach for Cancer Detection

The researchers report in Nature Communications that their liquid biopsy approach has high specificity in detecting all- and early-stage cancers.